Study: Buprenorphine-Naloxone Cuts Overdose Risk Better Than Naltrexone After Detox

A comprehensive analysis of more than 36,000 adults discharged from medically managed opioid withdrawal has found that patients who initiated buprenorphine-naloxone experienced significantly fewer nonfatal opioid overdoses over six months compared to those starting extended-release naltrexone. The study, published Tuesday in JAMA Network Open, offers new real-world evidence about how these two leading medications for opioid use disorder perform after the critical detoxification period.

Researchers from Massachusetts examined 106,052 discharge episodes between 2014 and 2018, tracking outcomes for 36,752 unique individuals. Within 28 days of leaving detox, 13.4% of patients started buprenorphine-naloxone while 4.5% initiated extended-release naltrexone—a disparity that itself highlights the accessibility challenges facing the monthly injection option.

The Overdose Gap Emerges

At 24 weeks following discharge, the data revealed a meaningful difference in nonfatal overdose rates. Patients on buprenorphine-naloxone experienced nonfatal overdoses at a rate of 11.6%, compared to 13.9% for those on extended-release naltrexone—a 2.3 percentage point gap that translates to substantially fewer traumatic overdose events.

Yet the study found no significant difference in all-cause mortality between the two groups, with both medications showing approximately 1.4% mortality over the follow-up period. This finding suggests that while buprenorphine-naloxone may prevent more nonfatal overdoses, both medications provide comparable protection against death when patients can access and maintain treatment.

Why the Difference Matters

The overdose disparity carries significant clinical weight. Even among patients who successfully initiated medication-assisted treatment after detox, roughly one in eight to one in seven experienced a nonfatal overdose within six months. These figures underscore a reality that addiction medicine specialists have long emphasized: medical detoxification addresses acute withdrawal but does not, by itself, treat the underlying opioid use disorder.

The researchers employed target trial emulation methodology to compare outcomes in a way that mimics randomized clinical trials, addressing the fact that clinicians do not randomly assign patients to different medications in real-world practice. This approach strengthens the study's applicability to everyday clinical decision-making.

Medication Mechanisms and Practical Barriers

Buprenorphine-naloxone functions as a partial opioid agonist combined with an opioid antagonist. It reduces withdrawal symptoms and cravings while carrying a ceiling effect that limits respiratory depression and overdose risk from the medication itself. Patients can typically start the sublingual formulation within days of completing detox, and the medication can be prescribed in outpatient settings.

Extended-release naltrexone operates differently. As a full opioid antagonist delivered via monthly intramuscular injection, it blocks opioid receptors entirely. However, this mechanism requires patients to achieve complete opioid abstinence before the first dose—a transition many find difficult immediately following detox. The injection also requires clinical administration, creating logistical barriers that the study's initiation rates reflect.

Retention Emerges as the Critical Factor

The study's authors emphasize that medication retention—whether patients continue taking their prescribed treatment over time—may matter more than which specific medication is chosen. Among patients who had not taken their medication on the day of an overdose event, rates climbed substantially higher than among those with recent medication exposure.

This finding reinforces the importance of care continuity in the weeks immediately following detox, when overdose risk peaks due to reduced tolerance and the psychological challenges of early recovery. The researchers noted that the majority of discharge episodes analyzed did not lead to either medication within 28 days—a gap they flagged as a separate problem requiring attention.

Implications for Treatment Systems

The Massachusetts data arrives as healthcare systems nationwide grapple with how to improve post-detox outcomes. While both medications are FDA-approved for opioid use disorder and recommended by clinical guidelines, their real-world effectiveness depends heavily on implementation—how easily patients can start treatment, maintain access, and receive supportive services.

For patients and families evaluating treatment options, the study suggests asking direct questions about how detox programs connect to ongoing medication-assisted treatment. Programs without clear pathways to buprenorphine-naloxone, naltrexone, or methadone leave a dangerous gap precisely when patients face elevated risk.

The research also highlights ongoing challenges in making extended-release naltrexone more accessible. Despite some patients preferring its once-monthly dosing and non-addictive profile, its three-fold lower initiation rate compared to buprenorphine-naloxone indicates systemic barriers that treatment systems have yet to resolve.

People seeking help for opioid addiction can find medication-assisted treatment programs that provide comprehensive care bridging detoxification and long-term recovery support.